Enhancing Language Function in Primary Progressive Aphasia

Status Recruiting

Clinical Trial Summary

This study's goal is to use non-invasive brain stimulation (NBS) techniques to treat language impairment associated with Primary Progressive Aphasia (PPA). The purpose of this study is to combine behavioral language intervention with individualized noninvasive brain stimulation techniques, called transcranial direct current stimulation (tDCS) to help the brain reorganize around damage and improve language functions.

Clinical Trial Description

Primary Progressive Aphasia (PPA) is a neurodegenerative disorder that selectively affects language comprehension and/or production, with initial preservation of other cognitive domains. As tDCS has not been extensively studied in PPA, the investigators will measure both short- and long-term effects of stimulation in patients with this neurodegenerative disorder that affects specific language regions. Previous research suggests that neurostimulation with tDCS can safely induce changes in neural plasticity that can lead to long-term restoration of synaptic function. Thus, individually targeted stimulation to structurally preserved but dysfunctional regions may be able to produce behavioral improvements in primary progressive aphasia (PPA). TDCS is a method of stimulating the brain that does not require any sedation or surgery. TDCS is a technique that sends a weak electrical current through the scalp to stimulate the brain areas below. The information gained from this research study will aid in the development of therapies to improve language in people with neurological conditions that affect language use. TDCS will be applied over the activated area identified with the functional magnetic resonance imaging (fMRI) fMRI-localizer task. This approach will allow for individually optimized tDCS electrode placement. It will also account for potential inter-participant variability in the brain atrophy and language organization Summary of study sequence and procedures: Week 1: Baseline screening, language testing, one event-related brain potential (EEG-ERP) session Weeks 2: fMRI session to determine most effective treatment Weeks 3-4: tDCS with Language Treatment Part 1 Weeks 5 and 6: rest-period, post-treatment assessment Weeks 7 to 8: TDCS with Language Treatment Part 2 Weeks 9 and 10: rest period, post-treatment assessment 2-month follow-up, language assessment, one MRI scan, one EEG-ERP session ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04920318
Study type	Interventional
Source	University of Arizona
Contact	Aneta Kielar, PhD
Phone	15204883791
Email	akielar@email.arizona.edu
Status	Recruiting
Phase	N/A
Start date	August 30, 2021
Completion date	June 15, 2026

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT04290988` - Circuitry Assessment and Reinforcement Training Effects on Recovery	N/A
Recruiting	`NCT04957537` - Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia	N/A
Completed	`NCT04045990` - Network Modulation in Alzheimer's Disease	N/A
Recruiting	`NCT05443633` - Enhancing Language Function in Aphasia	N/A
Completed	`NCT05860647` - Transmagnetic Stimulation Pilot in Primary Progressive Aphasia	N/A
Recruiting	`NCT03887481` - Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA	N/A
Completed	`NCT03728582` - Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy	N/A
Completed	`NCT01465360` - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center	N/A
Completed	`NCT02541097` - Preventing Language Decline in Dementia	N/A
Recruiting	`NCT00537004` - Language in Primary Progressive Aphasia
Recruiting	`NCT05741853` - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia	N/A
Active, not recruiting	`NCT05742698` - Nabilone for Agitation in Frontotemporal Dementia	Phase 2
Completed	`NCT02439853` - Communication Bridge Speech Therapy Research Study	N/A
Completed	`NCT01623284` - PiB PET Scanning in Speech and Language Based Dementias	Phase 1
Completed	`NCT04726527` - Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
Completed	`NCT03076671` - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease	N/A
Completed	`NCT05537688` - Identification of Graphic Markers of Neurocognitive Disorders (MG)
Completed	`NCT05525377` - Better Living With Non-memory-led Dementia	N/A
Completed	`NCT02928848` - Transcranial Direct Current Stimulation for Primary Progressive Aphasia	N/A
Completed	`NCT04939818` - Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Enhancing Language Function in Primary Progressive Aphasia — PPA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms